Petasol butenoate complex (Ze 339) relieves allergic rhinitis-induced nasal obstruction more effectively than desloratadine

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

卷:127

Article

Dumitru, Alina F.⁴  Shamji, Mohamed⁴  Wagenmann, Martin⁵  Hindersin, Simone⁵  Scheckenbach, Kathrin⁵  Greve, Jens⁶  Klenzner, Thomas⁵  Hess, Lorenzo⁷  Nebel, Sabine⁸  Zimmermann, Christian⁸  Zahner, Catherine⁸  Schmidt-Weber, Carsten B.^1,2,4  Chaker, Adam M.^3,4,5 

[1] Tech Univ Munich, Ctr Allergy & Environm ZAUM, D-80802 Munich, Germany

[2] Helmholtz Ctr Munich, D-80802 Munich, Germany

[3] Tech Univ Munich, Dept Otorhinolaryngol, D-80802 Munich, Germany

[4] Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, Sect Allergy & Clin Immunol, London SW7 2AZ, England

[5] Heinrich Heine Univ Hosp Dusseldorf, Dept Otorhinolaryngol, Dusseldorf, Germany

[6] Univ Duisburg Essen, Dept Otorhinolaryngol, Essen, Germany

[7] Brunner & Hess Software AG, Zurich, Switzerland

[8] Max Zeller Sohne AG, Romanshorn, Switzerland

关键词: Randomized controlled trial;    allergic rhinitis;    nasal obstruction;    rhinomanometry;    IL-8;    leukotriene B-4;    histamine;    Ze 339;    petasol butenoate complex;    Petasites hybridus;    desloratadine;    nasal allergen challenge;   

DOI  :  10.1016/j.jaci.2011.02.045

来源: Elsevier

【 摘 要 】

Background: Allergic rhinitis symptoms of itching, sneezing, rhinorrhea, and nasal obstruction significantly decrease patients' quality of life. Compared with histamine and leukotriene receptor antagonists, the petasol butenoate complex Ze 339 displays pharmacologically distinct properties. In vitro it inhibits the biosynthesis of leukotrienes and mediator release from activated eosinophils. Objective: This study aimed to assess the efficacy and mode of action of Ze 339, desloratadine, and placebo on allergic rhinitis symptoms, nasal airflow, and local mediator levels after unilateral nasal allergen provocation. Methods: In this double-blind, randomized, crossover study 18 subjects with allergic rhinitis to grass pollen received Ze 339, desloratadine, and placebo for 5 days before nasal allergen challenge with grass pollen extract. Rhinomanometry, symptom assessment, and local inflammatory mediator measurement were performed during the 24 hours after allergen challenge. Results: With Ze 339, the patient's time to recovery (5.4 +/- 1.6 hours) from nasal obstruction after allergen challenge (time for return to 90% of baseline value +/- SEM) was significantly shorter than with placebo (9.1 +/- 2.3 hours, P = .035) and desloratadine (10.7 +/- 2.5 hours, P = .022). Likewise, Ze 339's standardized symptom assessment for nasal obstruction (3.2 +/- 1.3 hours) showed significantly faster relief (time for return to baseline value +/- SEM compared with placebo, 8.3 +/- 2.4 hours; P = .027) and desloratadine (4.5 +/- 1.2 hours, P = .030). One interesting finding was that Ze 339 significantly reduced IL-8 and leukotriene B-4 levels in nasal secretions before challenge. Conclusion: When compared with desloratadine and placebo, Ze 339 shows better efficacy in relieving nasal obstruction symptoms and inhibiting critical components of the chemokine network and as such represents a novel symptomatic and possible prophylactic treatment for allergic rhinitis. (J Allergy Clin Immunol 2011;127:1515-21.)

【 授权许可】

Free